RRM2 and fibrosarcoma: Our finding showed that piR-39980 could attenuate the DOX resistance by repressing the expression of RRM2 and CYP1A2 in DOX-resistant fibrosarcoma cells (Supplementary Fig. 10) and hence could be a potential therapeutic agent for improving the clinical response of fibrosarcoma patients to DOX.